In addition, the reduction in SDF-1 expression by CRISPR-Cas9 (MSCsSDF-1−/−) can be used in anti-tumor therapies to increase macrophage activation and reduce their anti-inflammatory properties [147]. This evidence concerns the gene CXCL12 and neoplasm.